Megan O'Driscoll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Megan O'Driscoll has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Henrik Salje
Department of Genetics, University of Cambridge, Cambridge, United Kingdom
10 shared publications - Andrew S. Azman
Johns Hopkins University
6 shared publications - Daniel Mukadi-Bamuleka
Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of Congo
4 shared publications - Derek A. T. Cummings
Departments of Epidemiology and Biomedical Engineering, Johns Hopkins University, 615 N Wolfe St, Baltimore, MD 21205, United States
4 shared publications - Espoir Bwenge Malembaka
Center for Tropical Diseases and Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo
4 shared publications - Jackie Knee
London School of Hygiene and Tropical Medicine
4 shared publications
Latest Publications
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 207-215
The Incubation Periods of Mpox Virus Clade Ib
Mpox virus (MPXV) clade Ib, first detected in the Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting an emergency declaration from the World Health Organization. Data on its incubation period, which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. To estimate the incubation periods of mpox clade Ib, examining evidence for differences by route of exposure and demographic factors. Bayesian analysis of clinical surveillance data collected between June and October 2024. South Kivu, DRC, the epicenter of the current mpox clade Ib global outbreak. Clinically attended persons with confirmed mpox clade Ib infection. Demographic characteristics, exposure history, symptom onset, and transmission route. Among 37 polymerase chain reaction-confirmed cases with high viral load (cycle threshold values <34), the median incubation period from exposure to rash was 13.6 days (95% credible interval [CrI], 9.6 to 19.0 days). Five percent of cases are expected to develop a rash within 3.1 days (CrI, 1.3 to 5.5 days) and 95% within 32.3 days (CrI, 22.4 to 45.8 days). The incubation period seemed to differ by putative transmission route: Sexual transmission had a shorter median (10.3 days [CrI, 3.1 to 20.3 days]) than nonsexual transmission (13.5 days [CrI, 9.5 to 19.1 days]), although the CrIs overlapped. Surveillance data lacked detailed exposure histories and a lower bound for exposure periods, but models accounted for these uncertainties, yielding robust median estimates. Evidence from this study suggests that clade Ib may have a longer incubation period than other MPXV clades, and this may vary by transmission route. The shorter incubation for sexual transmission mirrors patterns seen in the predominantly sexually transmitted clade IIb outbreak, highlighting the potential role of exposure route in disease progression. These findings have implications for global recommendations on postexposure monitoring periods and prophylaxis. Gates Foundation and Geneva Centre for Emerging Viral Diseases.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 207-215
The Incubation Periods of Mpox Virus Clade Ib
Mpox virus (MPXV) clade Ib, first detected in the Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting an emergency declaration from the World Health Organization. Data on its incubation period, which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. To estimate the incubation periods of mpox clade Ib, examining evidence for differences by route of exposure and demographic factors. Bayesian analysis of clinical surveillance data collected between June and October 2024. South Kivu, DRC, the epicenter of the current mpox clade Ib global outbreak. Clinically attended persons with confirmed mpox clade Ib infection. Demographic characteristics, exposure history, symptom onset, and transmission route. Among 37 polymerase chain reaction-confirmed cases with high viral load (cycle threshold values <34), the median incubation period from exposure to rash was 13.6 days (95% credible interval [CrI], 9.6 to 19.0 days). Five percent of cases are expected to develop a rash within 3.1 days (CrI, 1.3 to 5.5 days) and 95% within 32.3 days (CrI, 22.4 to 45.8 days). The incubation period seemed to differ by putative transmission route: Sexual transmission had a shorter median (10.3 days [CrI, 3.1 to 20.3 days]) than nonsexual transmission (13.5 days [CrI, 9.5 to 19.1 days]), although the CrIs overlapped. Surveillance data lacked detailed exposure histories and a lower bound for exposure periods, but models accounted for these uncertainties, yielding robust median estimates. Evidence from this study suggests that clade Ib may have a longer incubation period than other MPXV clades, and this may vary by transmission route. The shorter incubation for sexual transmission mirrors patterns seen in the predominantly sexually transmitted clade IIb outbreak, highlighting the potential role of exposure route in disease progression. These findings have implications for global recommendations on postexposure monitoring periods and prophylaxis. Gates Foundation and Geneva Centre for Emerging Viral Diseases.
- Open Access
Comparative analytical sensitivity evaluation of five mpox point-of-care assays for mpox clades Ia, Ib, IIa and IIb
Backgrounds: Following an increase in mpox clade Ib cases in several African countries, the World Health Organization recognized mpox as a public health emergency of international concern, highlighting the need for reliable and accessible diagnostic tools. As several mpox clades are co-circulating in endemic countries, the analytical sensitivity of diagnostic assays should be evaluated for all of them in a comparative manner. Methods: This study evaluated the analytical sensitivity of three rapid tests (Flowflex Monkeypox virus rapid test from ACON Biotech, Monkeypox antigen rapid test from Assure Tech, and Standard Q Monkeypox Ag Test from SD Biosensor) and two point-of care molecular tests (SD Biosensor’s M10 and Cepheid’s Xpert MPOX assays) using serial dilutions of viral stocks from the four clades of Monkeypox virus (MPXV): Ia, Ib, IIa, and IIb. Findings: Upon our analytical comparative benchmarking, the three rapid tests demonstrated comparable analytical sensitivity for all four clades, with a limit of detection of approximately 1,000,000 DNA copies/mL or 1,000 FFU/mL. The two molecular tests demonstrated also comparable analytical sensitivity to an in-house PCR assay for all four clades, detecting concentrations down to 10-100 DNA copies per mL, corresponding to a non-detectable titer of infectious particles. The Xpert assay detected the Clade Ib strain only through its orthopoxvirus target and not its MPXV target, and none of the assays could distinguish between MPXV clades. Interpretation: No differences in sensitivity was observed across MPXV clades neither for Ag-RDTs nor for molecular POCTs. However, the potential of simple, affordable tests, such as Ag-RDTs, is limited by poor sensitivity while the use of highly sensitive POC molecular platforms remains limited by their cost. To date, the lack of accurate, affordable POC MPXV-specific assays with potential to differentiate clades, limits diagnostic capacities as well as our understanding of the virus and its epidemiology. Funding: This work was supported by FIND and internal funds of the Centre for Emerging Viral Diseases. Mpox diagnostic tests were provided by FIND and the World Health Organization (WHO). MOD was supported by Schmidt Science Fellows, in partnership with the Rhodes Trust.
Open AccessComparative analytical sensitivity evaluation of five mpox point-of-care assays for mpox clades Ia, Ib, IIa and IIb
Backgrounds: Following an increase in mpox clade Ib cases in several African countries, the World Health Organization recognized mpox as a public health emergency of international concern, highlighting the need for reliable and accessible diagnostic tools. As several mpox clades are co-circulating in endemic countries, the analytical sensitivity of diagnostic assays should be evaluated for all of them in a comparative manner. Methods: This study evaluated the analytical sensitivity of three rapid tests (Flowflex Monkeypox virus rapid test from ACON Biotech, Monkeypox antigen rapid test from Assure Tech, and Standard Q Monkeypox Ag Test from SD Biosensor) and two point-of care molecular tests (SD Biosensor’s M10 and Cepheid’s Xpert MPOX assays) using serial dilutions of viral stocks from the four clades of Monkeypox virus (MPXV): Ia, Ib, IIa, and IIb. Findings: Upon our analytical comparative benchmarking, the three rapid tests demonstrated comparable analytical sensitivity for all four clades, with a limit of detection of approximately 1,000,000 DNA copies/mL or 1,000 FFU/mL. The two molecular tests demonstrated also comparable analytical sensitivity to an in-house PCR assay for all four clades, detecting concentrations down to 10-100 DNA copies per mL, corresponding to a non-detectable titer of infectious particles. The Xpert assay detected the Clade Ib strain only through its orthopoxvirus target and not its MPXV target, and none of the assays could distinguish between MPXV clades. Interpretation: No differences in sensitivity was observed across MPXV clades neither for Ag-RDTs nor for molecular POCTs. However, the potential of simple, affordable tests, such as Ag-RDTs, is limited by poor sensitivity while the use of highly sensitive POC molecular platforms remains limited by their cost. To date, the lack of accurate, affordable POC MPXV-specific assays with potential to differentiate clades, limits diagnostic capacities as well as our understanding of the virus and its epidemiology. Funding: This work was supported by FIND and internal funds of the Centre for Emerging Viral Diseases. Mpox diagnostic tests were provided by FIND and the World Health Organization (WHO). MOD was supported by Schmidt Science Fellows, in partnership with the Rhodes Trust.
- Open Access
- 18 December 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (50)
Community transmission of mpox clade Ib not driven through sexual exposures, Uvira, eastern Democratic Republic of the Congo, June to October 2024
BACKGROUND: In September 2023, monkeypox virus (MPXV) clade Ib emerged in Kamituga, a mining zone in South Kivu, Democratic Republic of the Congo (DRC), primarily through sexual transmission. AIM: We aimed to investigate cases in a MPXV clade Ib outbreak in Uvira, eastern DRC. METHODS: From June to October 2024, we collected demographic, exposure and clinical data from suspected mpox cases at Uvira hospital and in households. The virus was identified by PCR. We investigated putative transmission patterns, disease severity and risk factors. RESULTS: We identified 973 suspected cases: 415 (42.7%) were tested with PCR and 322 (77.6%) were confirmed. The median age of suspected cases was 9 years (interquartile range (IQR): 3–20 years), with 620 (63.7%) aged < 15 and 344 (35.4%) < 5 years. Severe disease (≥ 100 lesions) was more common in cases aged < 15 years (25.6%; 142/554) than others (16.1%; 49/304; p < 0.001). Twenty-two (12.2%) of 181 cases aged < 5 years had acute malnutrition. Seven cases died; the overall case-fatality ratio was 0.7%, and in infants (aged < 1 year) it was 3.9% (5/127). Of 329 suspected cases tested for HIV, six (1.8%) were positive. Nineteen (14.5%) of 131 females aged 15–49 years were pregnant. Most reported exposures to suspected mpox cases occurred in households (67.9%; 298/439). Sexual (6.0%; 19/318) or healthcare-related occupational exposures (1.4%; 6/417) were less common. Animal exposures were few (5.0%; 39/776) and predominantly domestic (97.4%; 38/39). CONCLUSION: This child-centred outbreak, driven by non-sexual transmission, underscores the need for paediatric vaccines, nutritional support and household interventions. Adult-focused responses alone may be insufficient to control the outbreak.
- 18 December 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (50)
Open AccessCommunity transmission of mpox clade Ib not driven through sexual exposures, Uvira, eastern Democratic Republic of the Congo, June to October 2024
BACKGROUND: In September 2023, monkeypox virus (MPXV) clade Ib emerged in Kamituga, a mining zone in South Kivu, Democratic Republic of the Congo (DRC), primarily through sexual transmission. AIM: We aimed to investigate cases in a MPXV clade Ib outbreak in Uvira, eastern DRC. METHODS: From June to October 2024, we collected demographic, exposure and clinical data from suspected mpox cases at Uvira hospital and in households. The virus was identified by PCR. We investigated putative transmission patterns, disease severity and risk factors. RESULTS: We identified 973 suspected cases: 415 (42.7%) were tested with PCR and 322 (77.6%) were confirmed. The median age of suspected cases was 9 years (interquartile range (IQR): 3–20 years), with 620 (63.7%) aged < 15 and 344 (35.4%) < 5 years. Severe disease (≥ 100 lesions) was more common in cases aged < 15 years (25.6%; 142/554) than others (16.1%; 49/304; p < 0.001). Twenty-two (12.2%) of 181 cases aged < 5 years had acute malnutrition. Seven cases died; the overall case-fatality ratio was 0.7%, and in infants (aged < 1 year) it was 3.9% (5/127). Of 329 suspected cases tested for HIV, six (1.8%) were positive. Nineteen (14.5%) of 131 females aged 15–49 years were pregnant. Most reported exposures to suspected mpox cases occurred in households (67.9%; 298/439). Sexual (6.0%; 19/318) or healthcare-related occupational exposures (1.4%; 6/417) were less common. Animal exposures were few (5.0%; 39/776) and predominantly domestic (97.4%; 38/39). CONCLUSION: This child-centred outbreak, driven by non-sexual transmission, underscores the need for paediatric vaccines, nutritional support and household interventions. Adult-focused responses alone may be insufficient to control the outbreak.
- 26 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (826) , eads8680
Epidemiological and antigenic inferences from serological cross-reactivity among arboviruses
Multiplex immunoassays can facilitate the parallel measurement of antibody responses against multiple antigenically related pathogens, generating a wealth of high-dimensional data that depict complex antibody-antigen relationships. In this study, we developed a generalizable analytical framework to maximize inferences from multipathogen serological studies. We fit the model to measurements of immunoglobulin antibody binding against 10 arboviral pathogens from a cross-sectional study in northwest Bangladesh with 1453 participants. We used our framework to jointly infer the prevalence of each pathogen by location and age as well as between-pathogen antibody cross-reactivity. Reconstructing immunological profiles, we found evidence of endemic transmission of Japanese encephalitis virus and recent outbreaks of dengue and chikungunya viruses in this district. Our estimates of antibody cross-reactivity were highly correlated with phylogenetic distances inferred from genetic data [correlation coefficient ( r ) = 0.94], demonstrating how antigenic landscapes can be inferred from population-level serological studies. Furthermore, we showed how our framework could be used to identify the presence of antigenically related pathogens that were not directly tested for, representing a potential opportunity for the detection of emerging pathogens. The presented analytical framework offers a tool that can be applied to a growing number of multipathogen studies and will help support the integration of serological testing into disease surveillance platforms.
- 26 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (826) , eads8680
Epidemiological and antigenic inferences from serological cross-reactivity among arboviruses
Multiplex immunoassays can facilitate the parallel measurement of antibody responses against multiple antigenically related pathogens, generating a wealth of high-dimensional data that depict complex antibody-antigen relationships. In this study, we developed a generalizable analytical framework to maximize inferences from multipathogen serological studies. We fit the model to measurements of immunoglobulin antibody binding against 10 arboviral pathogens from a cross-sectional study in northwest Bangladesh with 1453 participants. We used our framework to jointly infer the prevalence of each pathogen by location and age as well as between-pathogen antibody cross-reactivity. Reconstructing immunological profiles, we found evidence of endemic transmission of Japanese encephalitis virus and recent outbreaks of dengue and chikungunya viruses in this district. Our estimates of antibody cross-reactivity were highly correlated with phylogenetic distances inferred from genetic data [correlation coefficient ( r ) = 0.94], demonstrating how antigenic landscapes can be inferred from population-level serological studies. Furthermore, we showed how our framework could be used to identify the presence of antigenically related pathogens that were not directly tested for, representing a potential opportunity for the detection of emerging pathogens. The presented analytical framework offers a tool that can be applied to a growing number of multipathogen studies and will help support the integration of serological testing into disease surveillance platforms.
- Open Access
The epidemiology of chikungunya virus in Brazil and potential impact of vaccines
The first chikungunya virus (CHIKV) vaccine is now licensed in Brazil, the country that reports most cases globally, however, the optimal use of the vaccine remains unclear due to a poor understanding of CHIKV epidemiology and population immunity. We quantified the annual CHIKV infection and disease burden since 2014 in each of the 27 Federal Units of Brazil using a mathematical model that integrated serological surveys (N=12), confirmed chikungunya cases (N=488,234) and chikungunya deaths (N=1,719) reported between January 2014 and September 2024. Using this base, we estimated the potential impact of a vaccine over the period 2025-2029 had the population been vaccinated before the 2025 season, evaluating different rollout strategies. We found that 18.3% (95%CrI: 16.5-20.3) of the population has been infected since 2014, with the highest risk concentrated in the Northeast and Southeast. Overall, 1.13% (95%CrI: 1.07-1.19) of infections were detected by surveillance systems, with an increasing probability of symptoms with age and greater risk of symptoms in females. Vaccinating 40% of the population aged >12y (73 million doses), and assuming a vaccine efficacy of 70% against infection and 95% against disease, would avert up to 1.6 million (95%CrI: 0.5-3) cases and 198 (95%CrI: 61-359) deaths over the next five years. Despite widespread circulation, most of the country remains vulnerable to infection. CHIKV vaccination has the potential to substantially reduce disease burden.
Open AccessThe epidemiology of chikungunya virus in Brazil and potential impact of vaccines
The first chikungunya virus (CHIKV) vaccine is now licensed in Brazil, the country that reports most cases globally, however, the optimal use of the vaccine remains unclear due to a poor understanding of CHIKV epidemiology and population immunity. We quantified the annual CHIKV infection and disease burden since 2014 in each of the 27 Federal Units of Brazil using a mathematical model that integrated serological surveys (N=12), confirmed chikungunya cases (N=488,234) and chikungunya deaths (N=1,719) reported between January 2014 and September 2024. Using this base, we estimated the potential impact of a vaccine over the period 2025-2029 had the population been vaccinated before the 2025 season, evaluating different rollout strategies. We found that 18.3% (95%CrI: 16.5-20.3) of the population has been infected since 2014, with the highest risk concentrated in the Northeast and Southeast. Overall, 1.13% (95%CrI: 1.07-1.19) of infections were detected by surveillance systems, with an increasing probability of symptoms with age and greater risk of symptoms in females. Vaccinating 40% of the population aged >12y (73 million doses), and assuming a vaccine efficacy of 70% against infection and 95% against disease, would avert up to 1.6 million (95%CrI: 0.5-3) cases and 198 (95%CrI: 61-359) deaths over the next five years. Despite widespread circulation, most of the country remains vulnerable to infection. CHIKV vaccination has the potential to substantially reduce disease burden.
- Open Access
Community transmission of Mpox clade Ib not driven through sexual exposures in Uvira, eastern Democratic Republic of Congo, June – October 2024
Introduction In September 2023, mpox clade Ib emerged in Kamituga, a mining zone in South Kivu, DR Congo, primarily through sexual transmission. This study investigates an mpox clade Ib outbreak in Uvira, an urban area 360 km from Kamituga, where the first case was reported in May 2024. Methods From June to October 2024, clinical and household data from suspected mpox cases were collected at Uvira hospital and household investigations. Mpox laboratory confirmation was performed via PCR. We analyzed demographic, exposure, and clinical data to characterize putative transmission patterns, severity, and risk factors. Results Among 973 suspected cases, 42.7% (415) had PCR results, with 77.6% (n=322) testing positive. The median age of suspected cases was 9 years (IQR: 3–20), with 63.7% under-15 (n=620) and 32.1% under-5 (n=312). Severe cases (≥100 lesions) were more frequent in children under 15 (25.6%, 142/554) than others (16.1%, 49/304; pConclusion This child-centered outbreak, driven by non-sexual transmission, underscores the need for pediatric vaccines, nutritional support, and household interventions. Adult-focused responses alone may be insufficient.
Open AccessCommunity transmission of Mpox clade Ib not driven through sexual exposures in Uvira, eastern Democratic Republic of Congo, June – October 2024
Introduction In September 2023, mpox clade Ib emerged in Kamituga, a mining zone in South Kivu, DR Congo, primarily through sexual transmission. This study investigates an mpox clade Ib outbreak in Uvira, an urban area 360 km from Kamituga, where the first case was reported in May 2024. Methods From June to October 2024, clinical and household data from suspected mpox cases were collected at Uvira hospital and household investigations. Mpox laboratory confirmation was performed via PCR. We analyzed demographic, exposure, and clinical data to characterize putative transmission patterns, severity, and risk factors. Results Among 973 suspected cases, 42.7% (415) had PCR results, with 77.6% (n=322) testing positive. The median age of suspected cases was 9 years (IQR: 3–20), with 63.7% under-15 (n=620) and 32.1% under-5 (n=312). Severe cases (≥100 lesions) were more frequent in children under 15 (25.6%, 142/554) than others (16.1%, 49/304; pConclusion This child-centered outbreak, driven by non-sexual transmission, underscores the need for pediatric vaccines, nutritional support, and household interventions. Adult-focused responses alone may be insufficient.
- Open Access
The incubation periods of Monkeypox virus clade Ib
Background Monkeypox virus (MPXV) clade Ib, first detected in Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting a WHO emergency declaration. Data on how this clade differs from others, including the incubation period which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. Methods We use clinical, laboratory and reported exposure data from suspected and qPCR-confirmed mpox cases in Uvira, DRC to estimate the incubation period for MPXV clade 1b. We developed a Bayesian model to estimate incubation periods of various symptom onset definitions (rash, fever, any symptom), demographic factors and putative transmission route (sexual vs. non-sexual). Results Among 92 PCR-confirmed cases, the median incubation period from exposure to rash was 18.6 days (95% CrI: 15.2-22.6). Five percent of cases are expected to develop a rash within 5.4 days (95% CrI; 3.4-7.6) and 95% within 37.6 days (95% CrI: 30.3-47.0). The incubation period differed by putative transmission route: sexual transmission had a shorter median (9.5 days, 95% CrI 3.7-16.4) than non-sexual transmission (18.9 days, 95% CrI: 15.3-23.0). Conclusions Incubation periods for clade Ib are longer than previous estimates for other MPXV clades, but vary strongly by sexual vs. non-sexual exposures, the former closely aligning with observations from the predominantly sexually transmitted clade IIa global outbreak. These findings highlight the significant differences by transmission route – likely reflecting differences in infectious viral dose and suggest the need to revise global post-exposure monitoring recommendations.
Open AccessThe incubation periods of Monkeypox virus clade Ib
Background Monkeypox virus (MPXV) clade Ib, first detected in Democratic Republic of the Congo (DRC) in September 2023, spread internationally within months, prompting a WHO emergency declaration. Data on how this clade differs from others, including the incubation period which both shapes outbreak dynamics and informs epidemic response strategies, remain limited. Methods We use clinical, laboratory and reported exposure data from suspected and qPCR-confirmed mpox cases in Uvira, DRC to estimate the incubation period for MPXV clade 1b. We developed a Bayesian model to estimate incubation periods of various symptom onset definitions (rash, fever, any symptom), demographic factors and putative transmission route (sexual vs. non-sexual). Results Among 92 PCR-confirmed cases, the median incubation period from exposure to rash was 18.6 days (95% CrI: 15.2-22.6). Five percent of cases are expected to develop a rash within 5.4 days (95% CrI; 3.4-7.6) and 95% within 37.6 days (95% CrI: 30.3-47.0). The incubation period differed by putative transmission route: sexual transmission had a shorter median (9.5 days, 95% CrI 3.7-16.4) than non-sexual transmission (18.9 days, 95% CrI: 15.3-23.0). Conclusions Incubation periods for clade Ib are longer than previous estimates for other MPXV clades, but vary strongly by sexual vs. non-sexual exposures, the former closely aligning with observations from the predominantly sexually transmitted clade IIa global outbreak. These findings highlight the significant differences by transmission route – likely reflecting differences in infectious viral dose and suggest the need to revise global post-exposure monitoring recommendations.
- Open Access
- 31 December 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (1)
Reconciling heterogeneous dengue virus infection risk estimates from different study designs
Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology is considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, has not been assessed. Using 26 y of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence were 1.75 to 4.05 times higher than case-derived FOI. Seroprevalence-derived was moderately correlated with case-derived FOI (correlation coefficient = 0.47) with slightly lower estimates. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis.
- 31 December 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (1)
Open AccessReconciling heterogeneous dengue virus infection risk estimates from different study designs
Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology is considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, has not been assessed. Using 26 y of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence were 1.75 to 4.05 times higher than case-derived FOI. Seroprevalence-derived was moderately correlated with case-derived FOI (correlation coefficient = 0.47) with slightly lower estimates. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis.
- Open Access
Epidemiological inferences from serological responses to cross-reacting pathogens
Multiplex immunoassays are facilitating the parallel measurement of antibody responses against multiple antigenically-related pathogens, generating a wealth of high-dimensional data which depict complex antibody-antigen relationships. In this study we develop a generalizable analytical framework to maximise inferences from multi-pathogen serological studies. We fit the model to measurements of IgG antibody binding to 10 arboviral pathogens from a cross-sectional study in northwest Bangladesh with 1,453 participants. We used our framework to jointly infer the prevalence of each pathogen by location and age, as well as the levels of between-pathogen antibody cross-reactivity. We find evidence of endemic transmission of Japanese encephalitis virus as well as recent outbreaks of dengue and chikungunya viruses in this district. Our estimates of antibody cross-reactivity were highly consistent with phylogenetic distances inferred from genetic data. Further, we demonstrated how our framework can be used to identify the presence of circulating cross-reactive pathogens that were not directly tested for, representing a potential opportunity for the detection of novel emerging pathogens. The presented analytical framework will be applicable to the growing number of multi-pathogen studies and will help support the integration of serological testing into disease surveillance platforms.
Open AccessEpidemiological inferences from serological responses to cross-reacting pathogens
Multiplex immunoassays are facilitating the parallel measurement of antibody responses against multiple antigenically-related pathogens, generating a wealth of high-dimensional data which depict complex antibody-antigen relationships. In this study we develop a generalizable analytical framework to maximise inferences from multi-pathogen serological studies. We fit the model to measurements of IgG antibody binding to 10 arboviral pathogens from a cross-sectional study in northwest Bangladesh with 1,453 participants. We used our framework to jointly infer the prevalence of each pathogen by location and age, as well as the levels of between-pathogen antibody cross-reactivity. We find evidence of endemic transmission of Japanese encephalitis virus as well as recent outbreaks of dengue and chikungunya viruses in this district. Our estimates of antibody cross-reactivity were highly consistent with phylogenetic distances inferred from genetic data. Further, we demonstrated how our framework can be used to identify the presence of circulating cross-reactive pathogens that were not directly tested for, representing a potential opportunity for the detection of novel emerging pathogens. The presented analytical framework will be applicable to the growing number of multi-pathogen studies and will help support the integration of serological testing into disease surveillance platforms.
- 13 May 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (7) , 1676-1685
Dynamics of measles immunity from birth and following vaccination
Measles remains a major threat to human health despite widespread vaccination. While we know that maternal antibodies can impair vaccine-induced immunity, the relative contributions of pre-existing immunity levels, maternal and infant characteristics on vaccine responses remain unclear, hampering evidence-based vaccination policy development. Here we combine serological data from 1,505 individuals (aged 0–12 years) in a mother–infant cohort and in a child cohort with empirical models to reconstruct antibody trajectories from birth. We show that while highly heterogeneous across a population, measles antibody evolution is strongly predictive from birth at the individual level, including following vaccination. Further, we find that caesarean section births were linked with 2.56 (95% confidence interval: 1.06–6.37) increased odds of primary vaccine failure, highlighting the long-term immunological consequences of birth route. Finally, we use our new understanding of antibody evolution to critically assess the population-level consequences of different vaccination schedules, the results of which will allow country-level evaluations of vaccine policy.
- 13 May 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (7) , 1676-1685
Dynamics of measles immunity from birth and following vaccination
Measles remains a major threat to human health despite widespread vaccination. While we know that maternal antibodies can impair vaccine-induced immunity, the relative contributions of pre-existing immunity levels, maternal and infant characteristics on vaccine responses remain unclear, hampering evidence-based vaccination policy development. Here we combine serological data from 1,505 individuals (aged 0–12 years) in a mother–infant cohort and in a child cohort with empirical models to reconstruct antibody trajectories from birth. We show that while highly heterogeneous across a population, measles antibody evolution is strongly predictive from birth at the individual level, including following vaccination. Further, we find that caesarean section births were linked with 2.56 (95% confidence interval: 1.06–6.37) increased odds of primary vaccine failure, highlighting the long-term immunological consequences of birth route. Finally, we use our new understanding of antibody evolution to critically assess the population-level consequences of different vaccination schedules, the results of which will allow country-level evaluations of vaccine policy.